Analyst Price Targets — KALA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 30, 2025 1:32 pm | — | Mizuho Securities | $1.50 | $1.81 | TheFly | Kala Bio downgraded to Neutral from Outperform at Mizuho |
| September 17, 2025 10:19 am | — | H.C. Wainwright | $35.00 | $17.47 | TheFly | Kala Pharmaceuticals price target raised to $35 from $12 at H.C. Wainwright |
| August 7, 2024 6:18 am | Yi Chen | H.C. Wainwright | $7.50 | $3.10 | TheFly | Kala Pharmaceuticals price target lowered to $15 from $18 at H.C. Wainwright |
| May 17, 2024 10:34 am | Yi Chen | H.C. Wainwright | $9.00 | $3.25 | TheFly | Kala Pharmaceuticals price target lowered to $18 from $21 at H.C. Wainwright |
| April 3, 2024 6:43 am | Yi Chen | H.C. Wainwright | $10.50 | $4.00 | StreetInsider | Kala Pharmaceuticals (KALA) PT Lowered to $21 at H.C. Wainwright |
Latest News for KALA
ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA” or the “Company”) today celebrated the landmark Executive Order signed by U.S. President Donald J.
Celularity (NASDAQ: CELU - Get Free Report) and KALA BIO (NASDAQ: KALA - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability. Valuation and Earnings This table compares Celularity and
Engagement will assess KALA's clinical assets, development options, and AI-enabled analytical opportunities, including the MSC Secretome platform Engagement will assess KALA's clinical assets, development options, and AI-enabled analytical opportunities, including the MSC Secretome platform
Next-Generation Agentic AI Platform Achieves Live Enterprise Deployment, Delivering Secure, Scalable, Autonomous Research Solutions to Global Biotechnology and Pharmaceutical Organizations Next-Generation Agentic AI Platform Achieves Live Enterprise Deployment, Delivering Secure, Scalable, Autonomous Research Solutions to Global Biotechnology and Pharmaceutical Organizations
The company confirmed that BIRA is now live in client-controlled environments, marking its entry into revenue-generating AI infrastructure.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KALA.
U.S. House Trading
No House trades found for KALA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.